The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Resistance mechanisms to anti-EGFR therapy in RAS/RAF wildtype colorectal cancer varies by regimen and line of therapy.
 
Christine Megerdichian Parseghian
No Relationships to Disclose
 
Ryan Sun
No Relationships to Disclose
 
Melanie Nicole Woods
No Relationships to Disclose
 
Stefania Napolitano
No Relationships to Disclose
 
Jumanah Alshenaifi
No Relationships to Disclose
 
Jason Willis
Honoraria - Cor2Ed
 
ShaKayla Kentel Nunez
No Relationships to Disclose
 
Alexey Sorokin
No Relationships to Disclose
 
Preeti Kanikarla Marie
No Relationships to Disclose
 
Kanwal Pratap Singh Raghav
Consulting or Advisory Role - AstraZeneca; Bayer; Daiichi Sankyo; Eisai
Speakers' Bureau - Bayer
Research Funding - Bayer (Inst); Daiichi Sankyo/Lilly (Inst); Guardant Health (Inst); Roche/Genentech (Inst)
 
Van K. Morris
Consulting or Advisory Role - Axiom Healthcare Strategies; Bicara Therapeutics; BioMedical Insights; Boehringer Ingelheim; Incyte; SERVIER
Research Funding - Bicara Therapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Immatics; Pfizer (Inst)
 
John Paul Y.C. Shen
Stock and Other Ownership Interests - Agios; Mirat; Syndax; Syndax
Consulting or Advisory Role - Engine Biosciences
Research Funding - Celsius Therapeutics; Celsius Therapeutics
 
Eduardo Vilar Sanchez
Consulting or Advisory Role - Janssen Research & Development; Recursion Pharmaceuticals
Patents, Royalties, Other Intellectual Property - The University of Texas MD Anderson Cancer Center, Vilar E, Chang K, Wu W, Bowen CM, Sinha K. Methods and Compositions Comprising MHC Class I Peptides, United States, 63/171,137, 4/6/2021, Filed (Provisional); The University of Texas MD Anderson Cancer Center, Vilar E, Wu W, Katayama H, Hanash S, Bommi P. Methods for Prognosing, Diagnosing, and Treating Colorectal Cancer, United States, 63/152,751, 2/23/2021, Filed (Provisional)
Travel, Accommodations, Expenses - Janssen Research & Development
 
Marko Rehn
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Agnes Ang
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Teresa Troiani
No Relationships to Disclose
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Iylon; Lutris; MolecularMatch
Consulting or Advisory Role - Abbvie; Amal Therapeutics; AstraZeneca/MedImmune; Bayer Health; Bicara Therapeutics; Boehringer Ingelheim; Boston Biomedical; Carina Biotech; Daiichi Sankyo; EMD Serono; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Frontier Medicines; Genentech; Genomic Health; Gilead Sciences; GlaxoSmithKline; HalioDx; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Lutris; Merck; Mirati Therapeutics; Natera; Novartis; Numab; Pfizer; Pierre Fabre; Redx Pharma; Repare Therapeutics; Replimune; Servier; Taiho Pharmaceutical; Xilis
Research Funding - Amgen; Array BioPharma; Biocartis; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; MedImmune; Novartis; Sanofi